Executive Management Team
Remy Luthringer, PhD
Executive Chairman & Chief Executive Officer
Remy Luthringer was named Executive Chairman of the Board on February 5, 2018 and has served as the Chief Executive Officer of Minerva Neurosciences, Inc. since November 2014. He has been involved in the development of more than 150 active molecules for clinical trials in the central nervous system. Dr. Luthringer is an Advisor at Medicxi Ventures, formerly Index Ventures, a venture capital firm comprising all of the life sciences portfolio companies, funds and team from Index Ventures.
Previously, he served as Chief Medical Officer for Index Ventures, with a focus on investments in healthcare infrastructure. He was also the head of the FORENAP Institute for Research in Neurosciences and Neuropsychiatry in France. Dr.
Luthringer has extensive experience in clinical psychiatric practice and holds a PhD in neurosciences and clinical pharmacology.
Rick Russell was appointed President of Minerva in December, 2017. Mr.
Russell has more than 20 years of experience leading commercial operations, including developing and implementing sales and marketing activities for major biotechnology and pharmaceutical brands in North America and the European Union. His commercial and operational expertise encompasses a number of therapeutic areas, including CNS disorders, neurodegenerative disorders, cardiovascular disease and women’s health.
Russell has held senior management positions at Ares Allergy Holdings, Stallergenes Greer, Inc., Sunovion, EMD Serono, Sanofi-Aventis and Novartis.
Geoff Race, FCMA, MBA
Executive Vice President, Chief Financial
Officer and Chief Business Officer
Prior to being named as Minerva Neurosciences’ CFO, Mr.
Race served as a consultant for the development of MIN-101 and MIN-117. He has previously served as Chief Executive Officer of Funxional Therapeutics Ltd., the lead program of which (FX125L) was acquired by Boehringer Ingelheim in 2012.
He also served as Chief Financial Officer at PanGenetics B.V. He is a Fellow of the Chartered Institute of Management Accountants and earned his MBA from Durham University Business School.
Michael Davidson, M.D.
Chief Medical Officer
Davidson has extensive experience in the research and development of drugs to treat diseases of the central nervous system.
He has been a consultant for a number of pharmaceutical and biotechnology companies, and is a board member and reviewer for several professional organizations and neuroscience and psychiatry publications.
Davidson has received the Neuroscience Award from the European College of Neuropsychopharmacology and from the International College of Neuropsychopharmacology. He is the recipient of over 50 research grants and has published over 300 articles primarily in peer reviewed journals in the areas of schizophrenia and Alzheimer’s disease.
Senior Vice President and Chief Operating Officer
Joe Reilly was most recently Vice President, Head of Commercial Strategy and Operations at Genzyme Corporation.
In more than a decade at Genzyme, he also served as Vice President of Global Business Operations, Vice President of Commercial Operations and Vice President of Finance in the Rare Diseases Division. Joe holds a BS and MS in Finance from Boston College.
Frederick Ahlholm, CPA
Senior Vice President and Chief Accounting Officer
Frederick Ahlholm was most recently Vice President of Finance and Chief Accounting Officer for Amarin Corporation plc, where he helped direct the growth of the company from a small clinical-stage drug developer into a commercial enterprise of more than 400 employees.Frederick is a CPA and earned his BBA at the University of Notre Dame.
Jay Saoud, PhD
Senior Vice President, Head of Research and Development
Saoud has more than 26 years of research and development experience in both industry and academia, where he played a critical role in the design, conduct and reporting of clinical trials across multiple therapeutic areas including CNS.
He was previously president and chief executive officer of PPRS Research, Inc., a strategic research and development consulting partner for Minerva. Dr.
Saoud has been involved in the development of more than 125 active molecules in multiple therapeutic areas. He has a record of successful pre-market and registration submissions in global regulatory jurisdictions and approval of 11 New Drug Applications (NDAs).
Senior Vice President, General Counsel
Devin Smith joined Minerva in July, 2018. Mr. Smith has more than 19 years of legal and compliance experience serving clients in the biotechnology and pharmaceutical industries.
He was previously General Counsel and Company Secretary of Stallergenes Greer plc, a global biopharmaceutical company focused on allergy immunotherapy products. Mr. Smith joined Stallergenes Greer from EMD Serono, Inc., the biopharmaceutical division of Merck KGaA, where he led the North American legal department as Vice President and General Counsel.
Executive Management Team
Prior to EMD Serono, he was a partner at the international law firm of Nixon Peabody LLP. Mr. Smith received a B.A.
from the University of North Carolina – Chapel Hill and his law degree (cum laude) from Suffolk University Law School.